Peptic ulcers are open sores that develop on the inside lining of the stomach and the upper portion of the small intestine. There are two types of peptic ulcers that include gastric ulcers and duodenal ulcers. Peptic ulcer disease (PUD) is a result of reduction in the thick layer of mucus that protects the stomach from digestive juices.The global peptic ulcer drugs market is estimated to account for US$ 45,951.2 Mn in terms of value by the end of 2027
Request a sample copy of this report:- https://www.coherentmarketinsights.com/insight/request-sample/3246
Increasing prevalence of peptic ulcers is a major factor boosting growth of the global peptic ulcer drugs market over the forecast period. For instance, according to the study, ‘A36 The Global Incidence of Peptic Ulcer Disease and Its Complications at The Turn Of The 21st Century: A Systematic Review’, published in the Journal of the Canadian Association of Gastroenterology in March 2018, Spain recorded the highest annual incidence of all PUD (complicated and uncomplicated) with 141.8 cases per 100,000 persons.
Moreover, change in lifestyle such as stress, diet, and high rate of smoking is also expected to propel growth of the market. For instance, according to the World Health Organization, 1.337 billion people smoked tobacco worldwide in 2018.North America region held dominant position in the global peptic ulcer drugs market in 2018, accounting for 41.4% share in terms of volume, followed by Europe.
Prolonged use of peptic ulcer drugs such as proton pump inhibitors and antibiotics may lead to increased risk of hip bone fracture as the ability to absorb calcium and iron decreases. Other side effects include, risk of opportunistic infections with S. pneumonia and C. defficile, owing to diminished natural gut flora. Such scenario is expected to hamper growth of the global peptic ulcer drugs market.Moreover, wide availability of generic drugs and poor patient compliance to medication in some countries is also expected to hamper growth of the market.
Key players in the market can focus on personalized treatment and management of patients suffering from PUD in order to enhance their market share. For instance, in July 2019, in a study published in the Journal of Clinical Medicine (MDPI), researchers from Institute of Medical Microbiology, Switzerland, concluded that next generation sequencing technology may facilitate rapid monitoring of virulence determinants in H. pylori, which may prove beneficial in personalized treatment and management of patients suffering from PUD.Moreover, high doses of nonsteroidal anti-inflammatory drug (NSAIDs) is associated with risk of recurrent PUD. Therefore, market players may focus on R&D in H. pylori eradication therapy as it has the potential to reduce the risk of recurrent PUD among NSAID users.
Key players in the market are focused on assessing the efficacy of potassium-competitive acid blocker in combination therapy for the treatment of PUD. For instance, in December 2019, Phathom Pharmaceuticals initiated pivotal phase III trial that is expected to assess the efficacy of Vonoprazan in combination with Amoxicillin against Vonoprazan in combination with Amoxicillin and Clarithromycin for the successful eradication of H. pylori infection.The U.S. FDA is currently reviewing the risk of Clostridium difficile–associated diarrhea (CDAD) in users of histamine H2 receptor blockers. H2 receptor blockers are used for the treatment of gastro esophageal reflux disease (GERD), stomach and small intestine ulcers, and heartburn.
Major players operating in the global peptic ulcer drugs market include, Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., Abbott Laboratories, AstraZeneca plc., RedHill Biopharma, Cadila Healthcare Ltd., Novitium Pharma LLC, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, and GlaxoSmithKline plc.
Key players in the market are focused on product approval and launch to expand their product portfolio. For instance, in November 2019, RedHill Biopharma received the U.S. FDA approval for Talicia, a treatment for Helicobacter pylori (H. pylori) infection in adults, regardless of ulcer status.In October 2019, Novitium Pharma LLC recalled ranitidine hydrochloride capsules (indicated for the treatment of duodenal ulcer) in the U.S., owing to potential N-Nitrosodimethylamine (NDMA) (a probable human carcinogen) amounts above levels established by the U.S. FDA.
Get the main link:- https://www.coherentmarketinsights.com/market-insight/peptic-ulcer-drugs-market-3246
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Visit our news Website: http://www.coherentchronicle.com/